CClinicalTrials.gg
RecruitingNCT07833007Updated Sep 22, 2026

Metabolic Syndrome Resposne to Dietary Limitations in Familial Mediterranean Fever in Adolescents

An interventional study of low calorie diet in Familial Mediterranean Fever (FMF ) and Metabolic Syndrome, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 13 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
13 Years to 17 Years
Sex
All
01

Study summary

metabolic syndrome may be prevalent in familial Mediterrean fever. Dietary limitations are main treatment in metabilc syndrome

Read the detailed description

forty metabolic syndrome participants (adolescents) with familial Mediterrean fever divided equally in to study group received low calorie diet for 3 months and control group who will no change their dietary habits

02

Conditions studied

  • Familial Mediterranean Fever (FMF )
  • Metabolic Syndrome
03

Who can participate

Ages eligible
13 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • metabolic syndrome
  • familial mediterreanean fever

Exclusion criteria

Exclusion Criteria:

  • cardiac diseases
  • repsiratory diseases
  • tumors
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group I

    twenty metabolic syndrome participants (adolescents) with familial Mediterrean fever will received low calorie diet for 3 months

    Behavioral: low calorie diet

  • No intervention
    group II

    Twenty metabolic syndrome participants (adolescents) with familial Mediterrean fever will no change their dietary habits for 12 weeks

Interventions

  • Behaviorallow calorie diet

    metabolic syndrome participants (adolescents) with familial Mediterrean fever will received low calorie diet for 3 months

05

What researchers measure

Primary outcomes

  1. fasting blood glcuose

    it will be assessed in plasma

    Time frame: it will be assessed after 12 weeks

Secondary outcomes

  1. body mass index

    it will be assessed while patients were on empty stomach and bladder

    Time frame: it will be assessed after 12 weeks

  2. waist circumference

    it will be assessed via tape measurement

    Time frame: it will be assessed after 12 weeks

  3. high density lipoprotein

    it will be assessed in plasma

    Time frame: it will be assessed after 12 weeks

  4. triglycerides

    it will be assessed in plasma

    Time frame: it will be assessed after 12 weeks

  5. systolic blood pressure

    it will be assessed from brachial artery

    Time frame: it will be assessed after 12 weeks

  6. diastolic blood pressure

    it will be assessed from brachial artery

    Time frame: it will be assessed after 12 weeks

  7. C reactive protein

    it will be assessed in plasma

    Time frame: it will be assessed after 12 weeks

06

Study locations

1 of 1 sites recruiting
  • Cairo University
    Giza, Dokki, Egypt
    Recruiting
07

Registry details

Key details

Study ID
NCT07833007
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (lecturer of department of physical therapy for cardiovascular respiratory disorder and geriatrics, Cairo University) — Principal investigator
First posted
Sep 22, 2026
Start date
Aug 10, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Sep 22, 2026

Study contacts

Ali Ismail, PhD
Contact
ali.mohamed@pt.cu.edu.eg
+201005154209
Ali mohamed, PhD
Contact
ali.mohamed@pt.cu.edu.eg
+201033321109
Ali MA Ismail, PHD
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion